GlassScriptPhysician profile
Anna M Elkins
NPI 1588095954
$3,607.36
in general payments reported to CMS, 2019-2025
25 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $388 · 2023: $757 · 2024: $856 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $558.99 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $466.65 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $354.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $333.93 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.02 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $107.98 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $94.69 | 2022-2025 | Breztri |
| Biohaven Pharmaceuticals, INC. | $76.07 | 2021 | |
| Merck Sharp & Dohme LLC | $72.65 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $41.94 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $36.76 | 2025 | Rexulti |
| Exact Sciences Corporation | $36.75 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $33.53 | 2024 | Otezla |
| Evoke Pharma, INC. | $33.04 | 2023 | Gimoti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.10 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.32 | 2025 | Caplyta |
| Dexcom, INC. | $24.99 | 2025 | Dexcom G6 Transmitter |
| Ars Pharmaceuticals Operations, INC. | $24.08 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $21.56 | 2023 | Auvelity |
| Astellas Pharma US INC | $17.45 | 2022 | |
| Currax Pharmaceuticals LLC | $16.15 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.30 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $14.56 | 2022 | |
| Amarin Pharma, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Elkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.